Baird lowered the firm’s price target on Owens & Minor to $18 from $21 and keeps a Neutral rating on the shares. The firm noted the Street is cautious over medical volumes, GLP-1 impacts in both segments particularly Patient Direct, PPE destocking, leverage, and more.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OMI: